Aquestive Therapeutics (AQST) Accumulated Depreciation & Amortization: 2017-2025
Historic Accumulated Depreciation & Amortization for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $43.9 million.
- Aquestive Therapeutics' Accumulated Depreciation & Amortization rose 1.25% to $43.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $174.8 million, marking a year-over-year increase of 1.34%. This contributed to the annual value of $43.5 million for FY2024, which is 1.44% up from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Accumulated Depreciation & Amortization is $43.9 million, which was up 0.30% from $43.8 million recorded in Q2 2025.
- Over the past 5 years, Aquestive Therapeutics' Accumulated Depreciation & Amortization peaked at $43.9 million during Q3 2025, and registered a low of $37.8 million during Q1 2021.
- For the 3-year period, Aquestive Therapeutics' Accumulated Depreciation & Amortization averaged around $43.2 million, with its median value being $43.2 million (2024).
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first dropped by 2.49% in 2021, then rose by 7.11% in 2022.
- Aquestive Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $39.9 million in 2021, then grew by 5.28% to $42.0 million in 2022, then increased by 2.19% to $42.9 million in 2023, then grew by 1.44% to $43.5 million in 2024, then rose by 1.25% to $43.9 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $43.9 million for Q3 2025, versus $43.8 million for Q2 2025 and $43.6 million for Q1 2025.